Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus
NCT07023406 · Type 2 Diabetes Mellitus (T2DM)
NCT06613854 · Type 2 Diabetes Mellitus (T2DM)
NCT06821399 · Diabetes, Diabetic Retinopathy, and more
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
Research Site
Phoenix, Arizona
Research Site
Concord, California
Research Site
La Jolla, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions